Trial reportDiabetologia2010
Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.
Trial report in Diabetologia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Effects of a Carbohydrate-Restricted Diet on β-Cell Response in Adults With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2025Trial
- Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle.Scientific reports · 2021Trial
- Exercise reduces body fat and improves insulin sensitivity and pancreatic β-cell function in overweight and obese male Taiwanese adolescents.BMC pediatrics · 2018Trial
- Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function.The Journal of clinical endocrinology and metabolism · 2016Trial
- IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.Journal of diabetes science and technology · 2015 · on this mapTrial
- A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.The Journal of clinical endocrinology and metabolism · 2015Trial
- Dapagliflozin lowers plasma glucose concentration and improves β-cell function.The Journal of clinical endocrinology and metabolism · 2015Trial
- Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.Arteriosclerosis, thrombosis, and vascular biology · 2013Trial
- Impact of Acute (Poly)Phenol-Rich Sugarcane Extract Consumption on Postprandial Glycemic Response in Healthy Adults: A Randomized Crossover Study.Foods (Basel, Switzerland) · 2026Article
- Decreased cardiovascular risk factors and inflammation with remission of type 2 diabetes in adults with obesity using a high protein diet: Randomized control trial.Obesity pillars · 2022Article
- Review
- Deep Resequencing of 9 Candidate Genes Identifies a Role for ARAP1 and IGF2BP2 in Modulating Insulin Secretion Adjusted for Insulin Resistance in Obese Southern Europeans.International journal of molecular sciences · 2022Article
- Hemoglobin structure at higher levels of hemoglobin A1C in type 2 diabetes and associated complications.Chinese medical journal · 2020Article
- Disposition Index in Active Acromegaly.Frontiers in endocrinology · 2019Article
- Article
- Benefits of combination low-dose pioglitazone plus fish oil on aged type 2 diabetes mice.Journal of food and drug analysis · 2018Article
- OGTT 1h serum C-peptide to plasma glucose concentration ratio is more related to beta cell function and diabetes mellitus.Oncotarget · 2017Article
- Differences in β-cell function and insulin secretion in Black vs. White obese adolescents: do incretin hormones play a role?Pediatric diabetes · 2017Article
- Glucose time series complexity as a predictor of type 2 diabetes.Diabetes/metabolism research and reviews · 2017Article
- Multi-parameter comparison of a standardized mixed meal tolerance test in healthy and type 2 diabetic subjects: the PhenFlex challenge.Genes & nutrition · 2017Article
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisThe aim of the study was to examine the determinants of oral glucose tolerance in 602 persons with impaired glucose tolerance (IGT) who participated in the Actos Now for Prevention of Diabetes (ACT NOW) study.
methodsIn addition to the 602 IGT participants, 115 persons with normal glucose tolerance (NGT) and 50 with impaired fasting glucose (IFG) were identified during screening and included in this analysis. Insulin secretion and insulin sensitivity indices were derived from plasma glucose and insulin during an OGTT. The acute insulin response (AIR) (0-10 min) and insulin sensitivity (S(I)) were measured with the frequently sampled intravenous glucose tolerance test (FSIVGTT) in a subset of participants.
resultsAt baseline, fasting plasma glucose, 2 h postprandial glucose (OGTT) and HbA(1c) were 5.8 +/- 0.02 mmol/l, 10.5 +/- 0.05 mmol/l and 5.5 +/- 0.04%, respectively, in participants with IGT. Participants with IGT were characterised by defects in early (DeltaI (0-30)/DeltaG (0-30) x Matsuda index, where DeltaI is change in insulin in the first 30 min and DeltaG is change in glucose in the first 30 min) and total (DeltaI(0-120)/DeltaG(0-120) x Matsuda index) insulin secretion and in insulin sensitivity (Matsuda index and S(I)). Participants with IGT in whom 2 h plasma glucose was 7.8-8.3 mmol/l had a 63% decrease in the insulin secretion/insulin resistance (disposition) index vs participants with NGT and this defect worsened progressively as 2 h plasma glucose rose to 8.9-9.94 mmol/l (by 73%) and 10.0-11.05 mmol/l (by 80%). The Matsuda insulin sensitivity index was reduced by 40% in IGT compared with NGT (p < 0.005). In multivariate analysis, beta cell function was the primary determinant of glucose AUC during OGTT, explaining 62% of the variance.
conclusionOur results strongly suggest that progressive beta cell failure is the main determinant of progression of NGT to IGT.
Indexed as
Identifiers
20012012What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.